Provides analytical testing and calibration services within the Indian healthcare sector, with operations based out of Indore. The cost structure is heavily employee-driven at 40.5% of revenue, with depreciation at 15.4% and materials at just 7.5% — a shape consistent with a people-and-equipment-intensive service model. Other operating expenses made up 25.7% of revenue, and capital expenditure ran at 16.5% of revenue. The business is family-promoted, with members of the founding family holding the Managing Director and Whole Time Director positions, and is listed on BSE. No segment-level revenue split is disclosed in the available filings. The company recorded an exceptional gain from the sale of an office flat during FY26. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Analytical testing and calibration services. Service-oriented, employee-intensive analytical testing and calibration
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 30 | 34 | 37 | 42 | 46 |
| EBITDA (ex other income) | 9 | 12 | 10 | 11 | 13 |
| margin % | 29.6 | 36.3 | 27.8 | 26.9 | 28.0 |
| Owners' profit | 0 | 3 | 1 | 2 | 2 |
| EPS, as reported (₹) | 0.30 | 4.61 | 1.59 | 2.19 | 2.82 |
| ROE % · ROCE % | 1.2 · 7.3 | 15.2 · 15.1 | 5.0 · 10.8 | 6.5 · 11.6 | 7.7 · 12.3 |
| Debt / equity (x) | 1.94 | 1.44 | 1.32 | 1.19 | 1.18 |
| Cash from operations | 8 | 8 | 12 | 12 | 9 |
| Capex | (1) | (4) | (4) | (7) | (8) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11 | 9 | 10 | 11 | 11 | 11 | 11 | 13 |
| Profit before tax | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Net profit | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| EPS (₹) | 0.60 | 0.22 | 0.15 | 1.32 | 0.55 | 0.35 | 0.45 | 1.47 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 27 Aug 2026 · Newspaper publication of 33rd AGM Notice | compliance | minimal | — | — |
| 27 Aug 2026 · Notice of 33rd AGM and Annual Report availability to shareholders | compliance | minimal | — | — |
| 25 Aug 2026 · Submission of 33rd Annual Report for FY 2025-26 and AGM Notice | compliance | minimal | — | — |
| 25 Aug 2026 · Choksi Laboratories 33rd AGM on 18 Sept 2026 via video conference | board shareholder meetings | low | — | — |
| 21 Aug 2026 · USFDA inspection at Indore lab finds 4 observations | regulatory legal | high | — | — |
| 21 Aug 2026 · Newspaper notice published for 33rd AGM via video conferencing | compliance | minimal | — | — |
| 13 Aug 2026 · Choksi Labs Q1 FY27 PAT up 51% YoY at Rs 58 lakh | results | high | — | — |
| 13 Aug 2026 · Q1 FY27 results approved; PAT up 51% YoY | results | high | — | — |
| 5 Aug 2026 · Board meeting on Aug 13 to approve Q1 FY27 results and other items | board shareholder meetings | low | — | — |
| 4 Aug 2026 · Choksi Laboratories changes RTA from MUFG Intime to Ankit Consultancy | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| NEPHROCARE HEALTH SERV L |
| 7,678 |
| 79.3 |
| 6.88 |
| 30.4 |
| 6.9 |
| 8.6 |
| — |
| 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 67.8 | 23.2 | 25 of 29 | 14% |
| P/B | 5.2 | 2.3 | 16 of 24 | 35% |
| ROCE | 6.5 | 6.1 | 14 of 29 | 54% |
| ROE | 7.7 | 7.3 | 13 of 26 | 52% |
| Debt / Equity | 1.2 | 0.0 | 25 of 26 | 4% |
| EBITDA margin | 28.9 | 25.6 | 10 of 24 | 61% |
| Revenue growth | 12.5 | 20.8 | 19 of 25 | 25% |
| Profit growth | 11.4 | 22.0 | 14 of 25 | 46% |
| Market cap | 133 | 38 | 12 of 30 | 62% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
